While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer ...

In a major strategic shift, Novo Nordisk has announced a significant workforce reduction, eliminating approximately 9,000 ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement ...

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of ...

Novo Nordisk, the drugmaker behind Ozempic, is laying off thousands of workers as it struggles against competition from other ...

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But ...

One of them is already a leader in the market for weight management drugs, and the other could join this field.

Consumer prices rose 2.9% in August from a year earlier, the Labor Department said Tuesday, the biggest increase since ...

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

Novo Nordisk, facing competition in the obesity drug market, has instructed employees to return to the office to enhance ...